LLM-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Cardiac Surgery Patients
- Sponsor
- Beijing Anzhen Hospital
- Study ID
- NCT07521488
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Aortic Aneurysm
- Aortic Dissection
- Cardiac Surgical Procedures
- Congenital Heart Disease
- Coronary Artery Bypass Grafting
- Heart Valve Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- LLM-Based Intelligent Health Management Assistant — OTHERA mobile application integrating large language model technology with individual health records. Participants upload multimodal clinical data including medical records, laboratory results, imaging data, and treatment histories to build a structured personal health profile. The assistant periodically incorporates the latest clinical practice guidelines and provides personalized lifestyle intervention recommendations, medication adherence reminders, and early warnings for potential health-critical events, in addition to standard clinical care.
Study Details
This is a single-center, prospective, randomized, open-label, parallel-controlled clinical study to evaluate the effectiveness of a large language model (LLM)-based intelligent health management assistant in the life-cycle health management of patients after cardiac surgery. A total of 500 adult patients who undergo cardiac surgery (including coronary artery bypass grafting, heart valve surgery, great vessel surgery, congenital heart disease correction, and other cardiac procedures) at Beijing Anzhen Hospital will be randomly assigned in a 1:1 ratio to an intervention group or a control group, stratified by age (\<65 vs ≥65 years) and surgery type. The intervention group will use the LLM-based mobile health management application in addition to standard postoperative care, while the control group will receive standard postoperative care alone. The application integrates multimodal clinical data into a personalized health profile and provides surgery-type-specific postoperative management recommendations, medication adherence reminders, complication early warning, and cardiac rehabilitation guidance. The primary outcome is the composite endpoint of major adverse cardiac and cerebrovascular events (MACCE), defined as all-cause death, non-fatal myocardial infarction, non-fatal stroke, or unplanned cardiovascular reoperation/reintervention, within 12 months after randomization. Secondary outcomes include health-related quality of life (EQ-5D-5L), cardiovascular rehospitalization rate, medication adherence (MMAS-8), postoperative complication rate, and cardiac rehabilitation achievement rate. Follow-up visits are scheduled at 1, 3, 6, 9, and 12 months post-randomization.
Key Dates
- First listed
- Apr 13, 2026
- Start date
- May 1, 2026
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 500 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: LLM-Based Health Management Assistant Plus Standard Care
- No Intervention: Standard Postoperative CareParticipants receive standard postoperative clinical care and follow-up, including routine outpatient visits, standard pharmacotherapy, and conventional discharge education.
Primary Outcome Measure
Composite Major Adverse Cardiac and Cerebrovascular Events (MACCE) [ Time Frame: Within 12 months after randomization ]
Central Contacts
- Ming Gong, MD+86 13901212470
Related Studies
- Molecular and Cellular Characterization of Cardiac Tissue in Postnatal DevelopmentRecruiting · Emory University · Atlanta, Georgia
- Endovascular Treatment of Thoracic Aortic DiseaseEnrolling By Invitation · Matthew Eagleton · Boston, Massachusetts
- Genetics of Congenital Heart DiseaseRecruiting · Nationwide Children's Hospital · Columbus, Ohio
- Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic PathologiesRecruiting · University of Alabama at Birmingham · Birmingham, Alabama